tashatuvango-shutterstock-com-2
Tashatuvango / Shutterstock.com
17 February 2016Americas

Galderma fends off Dr Reddy IPR claims

Galderma Laboratories has successfully avoided three inter partes review (IPR) petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.

More on this story

Generics
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.

More on this story

Generics
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.